Total 68Ga-DOTATATE-Avid Tumor Volume (TV) Predicts Progression-Free Survival (PFS) and Disease-Specific Mortality (DSM) in Patients with Neuroendocrine Tumors (NETs)

#1855

Introduction: Patients with NETs have divergent survival, even when having the same site of primary tumor, tumor stage and grade. 68Ga-DOTATATE PET/CT has emerged as a sensitive imaging modality for detecting NETs.

Aim(s): To determine if 68Ga-DOTATATE PET/CT imaging has any prognostic utility in patients with NETs.

Materials and methods: Patients with NETs (n=184) were enrolled in a prospective study of 68Ga-DOTATATE PET/CT imaging and comprehensive biochemical analysis. 68Ga-DOTATATE TV was measured in all participants. The primary outcome measures were PFS and DSM during a median follow-up time of 18 months (range 4–35).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Tirosh A, Papadakis G, Millo C, Sadowski S, Herscovitch P,

Keywords: PET, 68Ga-DOTATATE, mortality,